Patents Assigned to GUANGZHOU MEDICAL UNIVERSITY
  • Patent number: 11965187
    Abstract: A targeted DNA demethylation method (Mini-CRISD) and a fusion protein used in the method are provided. The Mini-CRISD method can targets delivery of demethylation activity through engineered miniature dCjCas9 to deliver engineered miniature ROS1 demethylation effector to specific DNA sequences and/or specific genomic locations (such as CpG islands) to achieve targeted demethylation of specific DNA.
    Type: Grant
    Filed: January 17, 2023
    Date of Patent: April 23, 2024
    Assignees: GUANGZHOU MEDICAL UNIVERSITY, GMU NEW DRUG DEVELOPMENT CO., LTD.
    Inventors: Xi-Yong Yu, Yu-Guang Zhu, Ao Shen, Ling-Min Zhang, Ji-Shuo Chang
  • Patent number: 11654126
    Abstract: The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 23, 2023
    Assignee: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae Lee, Fengyuan Yang, Liya Shen
  • Patent number: 11648291
    Abstract: The disclosure discloses a method of using PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof to inhibit a cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases. An amino acid sequence of the PRD peptide is SEQ ID NO: 1, an amino acid sequence of the PRD-S peptide is SEQ ID NO: 2, an amino acid sequence of the TAD peptide is SEQ ID NO: 3, and an amino acid sequence of the ZF7 peptide is SEQ ID NO: 4.
    Type: Grant
    Filed: August 2, 2021
    Date of Patent: May 16, 2023
    Assignee: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae Lee, Fengyuan Yang, Liya Shen, Dengxia Fan
  • Publication number: 20220160826
    Abstract: The disclosure discloses a method of using PRD, PRD-S, TAD, ZF7 peptide or a mixture thereof to inhibit a cellular response to inflammatory stimuli or treat cytokine-storm-mediated diseases.
    Type: Application
    Filed: August 2, 2021
    Publication date: May 26, 2022
    Applicant: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae LEE, Fengyuan YANG, Liya SHEN, Dengxia FAN
  • Publication number: 20210196660
    Abstract: The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.
    Type: Application
    Filed: August 13, 2020
    Publication date: July 1, 2021
    Applicant: GUANGZHOU MEDICAL UNIVERSITY
    Inventors: Jongdae LEE, Fengyuan YANG, Liya SHEN
  • Patent number: 10744152
    Abstract: The present invention discloses an Asarum total polysaccharide extract with antitussive activity, an extraction method thereof and an application in the preparation of a medicine for preventing and treating coughs. The present invention proves that the Asarum total polysaccharide extract has a significant effect of suppressing cough for the first time through a large number of pharmacodynamic tests, has the therapeutic effect approximate to codeine, has the effect of prolonging the cough latent period better than codeine, and also finds that the total Asarum polysaccharide extract has the effects of reducing the cough sensitivity and suppressing the airway inflammation for the first time, has excellent preventive and therapeutic effects on various types of coughs, and can be used for preparing the medicines for preventing and treating cough-related diseases.
    Type: Grant
    Filed: June 3, 2018
    Date of Patent: August 18, 2020
    Assignees: THE FIRST AFFILIATTED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY, GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE
    Inventors: Kefang Lai, Xiaodong Liu, Bonian Zhong, Shan Zhong, Yichu Nie
  • Patent number: 10501470
    Abstract: The invention discloses a use of asarinin in preparation of medicines for treating various coughs. The asarinin is used for preparing medicines for treating various coughs separately or in combination with other medicines. The asarinin can be extracted by an SFE-CO2 method. The asarinin and usable drug carriers or excipients are made into various formulations. And the formulations are granules, tablets, capsules, soft capsules, pills, dripping pills, ointments, syrups, injection, oral liquid, tinctures, sustained-releasing drugs, controlled release drugs or targeting preparations.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: December 10, 2019
    Assignees: THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY, GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE
    Inventors: Kefang Lai, Xiaodong Liu, Bonian Zhong, Shan Zhong, Chuqin Huang
  • Publication number: 20190161811
    Abstract: Disclosed in the present invention is a non-invasive detection method for screening for a well-developed blastocyst. A DNA methylation profile of a few of trophoblastic cells in a blastocyst is detected, and the average methylation level and the methylation pattern of embryos identified as having a good morphology in Gardner morphological blastocyst grading process are used as the standard for screening for well-developed blastocysts. The nearer the methylation level of the trophoblastic cells of the blastocyst to be tested approaches the methylation level or state of the good embryo, the better the embryo development is and the higher the suitability for being implanted into a maternal subject is. Furthermore, results of methylation sequencing may be analyzed to determine whether a chromosome is abnormal, so as to directly exclude chromosome-abnormal embryos.
    Type: Application
    Filed: April 11, 2017
    Publication date: May 30, 2019
    Applicants: Beijing Institute of Genomics, Chinese Academy of Sciences, Peking University Third Hospital, The Third Affiliated Hospital of Guangzhou Medical University
    Inventors: Jiang Liu, Jie Qiao, Guoqiang Li, Yang Yu, Yong Fan, Congru Li
  • Patent number: 10213095
    Abstract: The invention discloses a percutaneous puncture and dilation visible irrigation-suction system and a method of using the same. The system comprises a main tube, which is contiguous with the sheath tube and has an end for an endoscope insertion. The sheath tube comprises an inner sheath and an outer sheath joined together in a sleeve type. There is a space between inner and outer sheath. The inner sheath is connected to main tube, together building a channel via which the endoscope is inserted and withdrawn. The sheath tube is connected to main tube after completing puncture and dilation, then endoscope system is introduced for observation and operation. The present invention provides a percutaneous puncture and dilation visible irrigation-suction system and a method of using the same, with a continuous controllable visible negative pressure aspirator, achieving high irrigation and powerful suction efficiency, as well as clear endoscopic view.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 26, 2019
    Assignees: The First Affiliated Hospital of Guangzhou Medical University, Hangzhou Hawk Photoelectric Instrument Co., Ltd., Guangzhou Minitech Trade Company Ltd.
    Inventors: Guohua Zeng, Guohua Bao, Xinrong Lu, Lifang Hua, Jianqiang Ma
  • Publication number: 20160339054
    Abstract: The present invention discloses an Asarum total polysaccharide extract with antitussive activity, an extraction method thereof and an application in the preparation of a medicine for preventing and treating coughs. The present invention proves that the Asarum total polysaccharide extract has a significant effect of suppressing cough for the first time through a large number of pharmacodynamic tests, has the therapeutic effect approximate to codeine, has the effect of prolonging the cough latent period better than codeine, and also finds that the total Asarum polysaccharide extract has the effects of reducing the cough sensitivity and suppressing the airway inflammation for the first time, has excellent preventive and therapeutic effects on various types of coughs, and can be used for preparing the medicines for preventing and treating cough-related diseases.
    Type: Application
    Filed: March 25, 2015
    Publication date: November 24, 2016
    Applicants: THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY, GUANGZHOU INSTITUTE OF RESPIRATORY DISEASE
    Inventors: Kefang LAI, Xiaodong LIU, Bonian ZHONG, Shan ZHONG, Yichu NIE